SynthesisTranslational psychiatry2025
Neurophysiological biomarkers of treatment response in suicidal ideation: a systematic review.
Synthesis in Translational psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundSuicidal ideation (SI) is associated with increased morbidity and is one of the main modifiable risk factors for suicide. While initial evidence indicates the efficacy of several treatments for SI, most treatments were not developed to specifically target SI and are often associated with side effects or high relapse rates. Limited understanding of the neurophysiological basis of SI has hindered the optimization of these treatments.
methodsThis systematic review synthesizes the evidence on neurophysiological biomarkers associated with treatment-induced changes in SI in the context of clinical trials. A systematic literature of the Embase, PubMed, and PsycInfo databases was conducted according to the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines.
resultsTwenty-four articles were eligible for inclusion in this review, with most published within the past five years. The studies showed methodological heterogeneity, leading to limited convergence in findings. Many studies were limited by non-randomized study design, concurrent interventions, incomplete treatment protocols, and unvalidated assessments of SI. Despite these limitations, the findings suggest the involvement of the anterior cingulate cortex (ACC) in the anti-suicidal effects of intravenous (IV) ketamine. Notably, this effect was absent in patients treated with oral ketamine, possibly explaining the clinically superior anti-suicidal effects of IV-ketamine compared to the oral administration. Improvements in SI following electroconvulsive therapy and magnetic seizure therapy were associated with activity in the prefrontal cortex (PFC).
conclusionThese findings may indicate that the differential modulation of the ACC and PFC is linked to the acute, yet transient effects of IV-ketamine and the sustained effects of seizure therapies. Future studies designed to prospectively assess the efficacy of SI treatments should include these potential biomarkers of treatment response in their design.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.